KR20010006589A - Agent for treating urination disorder - Google Patents
Agent for treating urination disorder Download PDFInfo
- Publication number
- KR20010006589A KR20010006589A KR1020000003699A KR20000003699A KR20010006589A KR 20010006589 A KR20010006589 A KR 20010006589A KR 1020000003699 A KR1020000003699 A KR 1020000003699A KR 20000003699 A KR20000003699 A KR 20000003699A KR 20010006589 A KR20010006589 A KR 20010006589A
- Authority
- KR
- South Korea
- Prior art keywords
- agent
- urination disorder
- isoflavone
- therapeutic agent
- dry extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
본 발명은 배뇨 장해 치료제에 관한 것으로, 상세하게는 치료 효과가 개선된 배뇨 장해 치료제에 관한 것이다. 여기에서, 배뇨 장해 치료란 빈뇨의 경감, 야간 다뇨증의 경감, 일회 뇨량의 증가와 뇨방출력의 강화, 뇨 절단 해소, 배뇨 개시 곤란의 해소, 잔뇨와 체류뇨의 감소 등외에 뇨의를 상실하는 뇨실금 치료를 의미한다.The present invention relates to an agent for treating urination disorder, and more particularly, to an agent for treating urination disorder with improved therapeutic effect. Here, urination disorder treatment refers to urine that loses urine, besides reducing urinary frequency, reducing nocturnal polyuria, increasing urinary output and urinary output, eliminating urinary cleavage, eliminating difficulty in urination, and reducing residual urine and retention urine. Incontinence means treatment.
종래부터 배뇨 장해 치료제의 하나로서 호박 종자의 건조 엑기스가 알려져 있다. 구체적으로는 예컨대, 독일에 있어서 서양 호박 종자의 알코올 (60중량% 에탄올) 추출물의 건조에 의해 얻어진 호박 종자의 건조 엑기스는 과민 방광 (빈뇨, 핍박 뇨실금, 잔뇨감), 특히 여성의 배뇨 장해에 효과적이라고 알려져 있다 (Kommission E. monograph NO.11/199l.01.17.).Background Art Dry extract of pumpkin seeds has been known as one of the treatments for urination disorders. Specifically, the drying extract of pumpkin seeds obtained by drying the alcohol (60 wt% ethanol) extract of Western pumpkin seeds in Germany, for example, is effective for overactive bladder (urinary, persecution urinary incontinence, residual urine), especially for women with urination disorders. It is known as Kommission E. monograph NO.11 / 199l.01.17.
또한, 호박 종자 성분과 작용의 관계에 있어서도 연구되고, 리놀레산에 의한 배뇨 작용 등이 분명하게 되어 있다 (1990년 Urologe [B] 3O:62 내지 66페이지, 베를린 자유대학 H. Schiloioher 교수, 비뇨기과 의사 H. J. Schneider 참조).In addition, studies have been made on the relationship between pumpkin seed components and action, and urinary action by linoleic acid has been clarified. (1990 Urologe [B] 3O: pages 62 to 66, Professor H. Schiloioher, Free University of Berlin, Urology HJ See Schneider).
본 발명의 목적은 유효 성분으로서 호박 종자의 건조 엑기스를 함유하는 상기와 같은 공지의 배뇨 장해 치료제에 다른 성분을 배합하는 것에 의해 치료 효과가 개선된 배뇨 장해 치료제를 제공하는 것에 있다.An object of the present invention is to provide a urination disorder therapeutic agent having improved therapeutic effect by blending another component into the above known urination disorder therapeutic agent containing a dry extract of pumpkin seeds as an active ingredient.
본 발명자는 상기의 목적을 달성하기 위해 예의 검토한 결과, 식물 에스트로겐을 함유하는 각종 식물 중에 유리 또는 배당체로서 존재하는 이소플라본에 의해 유효 성분으로서 호박 종자의 건조 엑기스를 함유하는 배뇨 장해 치료제의 효과가 현저하게 개선된다는 놀라운 발견을 하였다.As a result of earnestly examining in order to achieve the above object, the present inventors have found that the isoflavone which is present as a free or glycoside in various plants containing phytoestrogens has an effect of treating urination disorders containing dry extract of pumpkin seeds as an active ingredient. A surprising discovery was made that it is significantly improved.
본 발명은 상기의 발견에 근거하여 완성된 것이며, 그 요지는 유효 성분으로서 호박 종자의 건조 엑기스와 이소플라본을 함유하고, 호박 종자의 건조 엑기스: 이소플라본의 배합 비율이 99:1 내지 80:20중량비인 것을 특징으로 하는 배뇨 장해 치료제에 있다.This invention was completed based on the said discovery, The summary contains the dry extract and isoflavone of a pumpkin seed as an active ingredient, The blending ratio of the dry extract of a pumpkin seed: isoflavone is 99: 1-80:20 It is in the urination disorder therapeutic agent characterized by the weight ratio.
이하, 본 발명을 상세히 설명한다. 본 발명은 이소플라본을 병용하는 것에 의해 호박 종자의 건조 엑기스를 유효 성분으로서 함유하는 배뇨 장해 치료제의 효과를 개선하는 것이다. 따라서, 베이스로서 사용되는 배뇨 장해 치료제의 종류는 그 유효 성분이 호박 종자의 건조 엑기스인 한 특별히 제한되지 않는다.Hereinafter, the present invention will be described in detail. This invention improves the effect of the urination disorder therapeutic agent which contains the dry extract of a pumpkin seed as an active ingredient by using isoflavone together. Therefore, the kind of urination disorder therapeutic agent used as the base is not particularly limited as long as the active ingredient is a dry extract of pumpkin seeds.
또한 성숙한 호박 종자의 성분은 약 1중량%의 스테롤와 스테로글리코사이드, 35 내지 53중량%의 지방유와 지방산, 6 내지 10중량%의 탄수화물, 4 내지 6중량%의 섬유로 이루어진다. 그리고, 지방산으로서 리놀레산 외에, 미소 성분으로서 토코페롤, 인지질, 트립신장해단백, 티테르펜, 스쿠알렌, 카르복시산, 쿠클비톨, 희소 아미노산, 카로티노이드류, 크립토크산틴, 망간, 아연, 마그네슘염 등을 함유한다.In addition, the components of mature pumpkin seeds consist of about 1% by weight of sterols and steroglycosides, 35 to 53% by weight of fatty oils and fatty acids, 6 to 10% by weight of carbohydrates, and 4 to 6% by weight of fibers. In addition to linoleic acid as a fatty acid, tocopherol, phospholipids, tryptic protein, titerpene, squalene, carboxylic acid, cucklebitol, rare amino acids, carotenoids, kryptoxanthin, manganese, zinc, magnesium salts and the like are contained as microcomponents.
호박 종자의 건조 엑기스로는 예컨대, 상술한 바와 같이 독일에서 있어서, 배뇨 장해 치료제로서 인지되어 있는 건조 엑기스 즉, 서양 호박 종자 특히, 큐카비타 페포 라인 (Cucurbita e pepo Linne) 종자의 알코올 (60중량% 에탄올)추출물을 건조하여 얻어진 호박 종자의 건조 엑기스를 적합하게 사용할 수 있다. 또, 이러한 호박 종자의 건조 엑기스는 예컨대, 아스크 약품 주식회사에 의해 시판되고 있기 때문에 용이하게 입수할 수 있다.As a dry extract of pumpkin seeds, for example, alcohol (60% by weight) of dry extracts known in Germany as a therapeutic agent for urination disorders, that is, Western pumpkin seeds, particularly Cucurbita e pepo Linne seeds, as described above. Dry extract of the pumpkin seeds obtained by drying the ethanol) extract can be suitably used. Moreover, since the dry extract of such a pumpkin seed is marketed, for example by Ask Chemical Co., Ltd., it can be obtained easily.
한편, 이소플라본은 식물 에스트로겐을 함유하는 각종 식물에 있어서, 유리 또는 배당체로서 존재하는 것으로 알려진 화합물이다. 식물 에스트로겐을 함유하는 식물로서는 명아주과; 사탕무우 등, 아스테라세아에과 (Asteraceae); 해바라기 등, 브라시카세아에과 (Brassicaceae); 브라시카세아에등, 유포비아세아에과 (Euphorbiaceae); 아주까리 등, 포아세아에과 (Poaceae); 보리, 밀, 벼, 호밀 등, 라미알레스과 (Lamiales); 세이지 등, 레구미노사에과 (Leguminosae); 알파파 (Alfalfa), 클로버, 콩, 가우크루아 (Gaukurua) 등, 릴리아세아에과 (Liliaceae); 마늘 등, 말바세아에과 (Malvaceae); 홀리 혹 (Holly Hock) 등, 아레카세아에과 (Arecaceae); 야쯔메 (八目) 코코넛 등, (버들)여뀌과; 식용 대황 등, 장미과: 사과, 벚꽃, 살구 등, 루비아세아과 (Rubiaceae); 커피 등, 버드나무과; 버드나무 등, 솔란아세아에과 (Solanaceae); 감자 등, 아피아세아에과 (Apiaceae); 파슬리 등을 들 수 있다.Isoflavones, on the other hand, are compounds known to exist as free or glycosides in various plants containing phytoestrogens. As a plant containing phytoestrogens, it is a quinine fruit family; Beet, etc., Asteraceae; Sunflower etc., Brassicaaceae; Brassicaea et al., Euphorbiaaceae; Castor et al., Poaceae; Barley, wheat, rice, rye, etc. Lamiales; Sage et al., Leguminosae; Alfalfa, clover, soybean, Gaukurua, etc., Liliaceae; Garlic et al., Malvaceae; Holly Hock et al., Arecaceae; Yatsume coconut, etc. Edible rhubarb and the like, rosaceae: apples, cherry blossoms, apricots, etc., Rubiaceae; Willow, such as coffee; Willow et al., Solanaceae; Potatoes et al., Apiaceae; Parsley, etc. are mentioned.
본 발명에 있어서, 특히 콩 또는 가우크루아로부터 추출된 이소플라본 (소위 콩 이소플라본)이 적합하게 사용된다. 이러한 이소플라본은 콩을 통해서 섭취하는 것에 의한 건강상 뛰어난 효과가 주목되고 있다. 그리고, 콩 (주로 배축)으로부터 분리, 농축, 정제한 이소플라본은 예컨대, 주식회사 상반 (常磐) 식물 화학 연구소에 의해 시판되고 있기 때문에 용이하게 입수할 수 있다.In the present invention, in particular, isoflavones (so-called soybean isoflavones) extracted from soybean or gau croa are suitably used. This isoflavone has been noted for its excellent health effects by ingesting it through soybeans. Since isoflavones separated, concentrated, and purified from soybeans (mainly embryonic) are commercially available from, for example, Sangban Plant Chemical Research Institute, they can be easily obtained.
본 발명의 배뇨 장해 치료제는 상기와 같은 호박 종자의 건조 엑기스와 이소플라본을 유효 성분으로서 함유하여 이루어지지만, 호박 종자의 건조 엑기스: 이소플라본의 배합 비율은 99:1 내지 80:20중량비가 된다.Although the urination disorder treatment agent of this invention contains the above-mentioned dry extract of pumpkin seed and isoflavone as an active ingredient, the blending ratio of the dry extract of a pumpkin seed: isoflavone becomes 99: 1-80:20 weight ratio.
이소플라본의 배합 비율이 상기의 범위보다 적은 경우는 배뇨 장해 치료제에 대한 이소플라본의 치료 효과 개선이 충분히 발현되지 않는다. 반면, 이소플라본의 배합 비율이 상기의 범위보다 많은 경우는 배뇨 장해 치료제로서의 원래 유효 성분인 호박 종자의 건조 엑기스 함유량이 저하하기 때문에 배뇨장해치료 효과가 떨어진다.When the blending ratio of isoflavone is less than the above range, the improvement of the therapeutic effect of isoflavone on the urination disorder therapeutic agent is not sufficiently expressed. On the other hand, when the blending ratio of isoflavone is larger than the above range, the dry extract content of the pumpkin seed, which is the original active ingredient as a urination disorder treatment agent, is lowered, so the effect of treating urination disorder is inferior.
본 발명의 배뇨 장해 치료제의 제형은 상술한 유효 성분 모두가 분말 형태로서 입수 가능하기 때문에 통상, 분말제, 과립제, 정제일 수 있지만, 특히 정제가 바람직하다. 정제화의 경우, 종래 공지의 부형제나 그 밖의 첨가제를 적시 사용할 수 있다. 부형제나 그 밖의 첨가제로서는, 예컨대, 맥아 덱스트린, 유당(DMV), 옥수수 전분 (콘스타치), (β-사이클로) 덱스트린, 결정 셀룰로오스, 칼메로스칼슘 등을 들 수 있다.The formulation of the therapeutic agent for treating urination disorders of the present invention may generally be a powder, granules, tablets because all of the above-mentioned active ingredients are available in powder form, but tablets are particularly preferred. In the case of tableting, conventionally well-known excipients and other additives can be used timely. Examples of excipients and other additives include malt dextrin, lactose (DMV), corn starch (cornstarch), (β-cyclo) dextrin, crystalline cellulose, and calmerose calcium.
본 발명의 배뇨 장해 치료제는 호박 종자의 건조 엑기스를 사용한 종래 공지의 배뇨 장해 치료제와 비교한 경우, 소량 일정량의 이소플라본이 배합되어 있는 점을 제외하고 같기 때문에 그 투여량은 상기의 같은 종래 공지의 배뇨 장해 치료제와 동일하게 결정할 수 있다. 구체적으로는, 호박 종자의 건조 엑기스 양으로 1일 당, 통상 200 내 500mg, 바람직하게는 300 내지 400mg이 된다. 그리고, 통상은 3회에 나누어 투여된다.Since the urination disorder treatment agent of the present invention is the same as the conventional known urination disorder treatment agent using dry extract of pumpkin seeds, except that a small amount of isoflavone is blended, the dosage is the same as that of the conventionally known It can be determined in the same manner as the treatment for urination disorder. Specifically, the amount of dry extract of pumpkin seeds is usually 500 mg, preferably 300 to 400 mg in 200 per day. Then, it is usually divided into three times and administered.
실시예Example
이하, 본 발명을 실시예에 의해 더욱 상세히 설명하지만, 본 발명은 그 요지를 넘지 않은 한 이하의 실시예에 한정되는 것이 아니다.Hereinafter, although an Example demonstrates this invention still in detail, this invention is not limited to a following example, unless the summary is exceeded.
실시예 1 및 비교예 1Example 1 and Comparative Example 1
<배뇨 장해 치료제의 조제><Preparation of urination obstacle therapeutic agent>
표 1에 나타난 각 성분으로부터 통상의 방법에 따라 1알 250mg의 본 발명의 배뇨 장해치료제를 조제하였다 (실시예 1). 또, 표 1의 중량은 6알에 대한 수치이다.From each component shown in Table 1, one tablet of 250 mg of the urination disorder treatment agent of the present invention was prepared according to a conventional method (Example 1). In addition, the weight of Table 1 is a numerical value with respect to 6 tablets.
표 1Table 1
상기 실시예 1에 있어서, 콩 이소플라본을 제외한 다른 성분을 사용한 것을 제외하고는 실시예 1과 동일하게 하여 l알 250mg의 비교용 배뇨 장해 치료제를 조제하였다 (비교예 1).In Example 1, except for using the other components except soy isoflavones in the same manner as in Example 1 to prepare a comparative 250 mg urine therapeutic agent for l grains (Comparative Example 1).
<배뇨 장해 치료제의 효과><Effect of urination disorder therapeutic agent>
야간의 배뇨회수가 3회 이상인 빈뇨 환자 50명을 무작위로 같은 명수의 A 및 B의 2군으로 나누고, A군에 대하여는 실시예 1의 배뇨 장해 치료제를 투여하고, B군에 대하여는 비교예 1의 배뇨 장해 치료제를 투여하였다. 투여량은 어느 쪽이든 아침, 점심, 저녁에 각기 2알 (1일 6알)로 하였다. 그리고, 투여 개시 후, 야간의 배뇨 회수가 1회로 감소하는 각 환자의 일수로부터 군의 평균 일수를 구하였다. 그 결과, 실시예 1의 배뇨 장해 치료제의 경우 평균 일수는 4일이고, 비교예 1의 배뇨 장해 치료제의 경우 평균 일수는 24일 이었다.50 patients with frequent urination with at least three times of night urination were randomly divided into two groups of A and B of the same number, group A was administered the therapeutic agent for urination disorder of Example 1, and group B of Comparative Example 1 The treatment for urination disorder was administered. The dosage was either 2 tablets (6 tablets per day) in the morning, lunch, and dinner. And after the start of administration, the average number of days in the group was determined from the days of each patient whose number of nighttime urinations decreased by one. As a result, the average days were 4 days for the urination disorder treatment agent of Example 1, and the average days were 24 days for the urination disorder treatment agent of Comparative Example 1.
이상 설명한 본 발명에 의하면 유효 성분으로서 호박 종자의 건조 엑기스를 함유하는 공지의 배뇨 장해 치료제에 이소플라본을 배합하는 것에 의해 치료 효과의 개선된 배뇨 장해 치료제가 제공된다.According to the present invention described above, an isoflavone is combined with a known urination disorder therapeutic agent containing a dry extract of pumpkin seeds as an active ingredient, thereby providing an improved urination disorder therapeutic agent.
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11097212A JP2000290192A (en) | 1999-04-05 | 1999-04-05 | Therapeutic agent for dysuria |
JP11-97212 | 1999-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010006589A true KR20010006589A (en) | 2001-01-26 |
Family
ID=14186327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000003699A KR20010006589A (en) | 1999-04-05 | 2000-01-26 | Agent for treating urination disorder |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2000290192A (en) |
KR (1) | KR20010006589A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107596077A (en) * | 2017-11-08 | 2018-01-19 | 马敏 | A kind of medicine for treating person in middle and old age's enuresis and preparation method thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050143323A1 (en) * | 2003-12-30 | 2005-06-30 | Henley E. C. | Isoflavone therapy for treating urinary incontinence |
KR100462173B1 (en) * | 2004-06-08 | 2004-12-16 | 안국약품 주식회사 | A composition for prevention and treatment of urinary incontinence |
JP5615484B2 (en) * | 2008-01-15 | 2014-10-29 | 株式会社 エス・ネット | 5α-reductase inhibitor |
CN104096103A (en) * | 2014-07-12 | 2014-10-15 | 张相骋 | Traditional Chinese medicine agent for treating uroschesis |
TR201703079A2 (en) * | 2017-02-28 | 2017-07-21 | Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret Anonim Sirketi | THE USE OF A VEGETABLE FORMULATION CONTAINING PUMPKIN SEED OIL IN THE TREATMENT OF BPH |
TR201703084A2 (en) * | 2017-02-28 | 2017-07-21 | Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret Anonim Sirketi | THE USAGE OF A VEGETABLE FORMULATION CONTAINING PUMPKIN SEED OIL IN THE TREATMENT OF THE EXTREMELY ACTIVE BLADDER AND URINARY INCONTINENCE RELATED LOWER URINARY SYSTEM SYMPTOMS |
-
1999
- 1999-04-05 JP JP11097212A patent/JP2000290192A/en active Pending
-
2000
- 2000-01-26 KR KR1020000003699A patent/KR20010006589A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107596077A (en) * | 2017-11-08 | 2018-01-19 | 马敏 | A kind of medicine for treating person in middle and old age's enuresis and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2000290192A (en) | 2000-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dubey et al. | A multipurpose tree-Moringa oleifera | |
Anuar et al. | Effect of green and ripe Carica papaya epicarp extracts on wound healing and during pregnancy | |
EP0282002B1 (en) | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care | |
Toma et al. | Phytochemistry and pharmacological activities of Moringa oleifera | |
JP3966689B2 (en) | Lipase inhibitor | |
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
JP2005060334A (en) | Anti-obesity agent having lipase inhibiting activity and antioxidation activity | |
JP2022079461A (en) | Composition for remedying female climacteric syndrome symptoms | |
JP2001342142A (en) | Composition for preventing and curing urologic disease | |
KR20010006589A (en) | Agent for treating urination disorder | |
KR102078832B1 (en) | Pharmaceutical composition for prevention or treatment of muscular disease comprising Panax ginseng berry extract as an active ingredient | |
JP2006290782A (en) | Antiedemic composition | |
KR20170121532A (en) | Composition for relieving menopausal symptom or osteoporosis | |
CN109645232A (en) | A kind of Chinese herbal medicine composite feed additive for treating animal diarrhea | |
JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
KR101847497B1 (en) | Pharmaceutical composition for preventing or treating of gynecologic disorders comprising extract of sarcodon asparatus as an ative ingredient | |
KR20150083168A (en) | Cosmetic composition for relieving swelling of face | |
EP2022345A1 (en) | Food composition for functional foods and nutritional supplements | |
JP4824205B2 (en) | Female hormone abnormal disorder improving agent | |
JP2021508258A (en) | Dietary supplements for menstruation and their use | |
Oko et al. | Pharmacognosy of Aspilia africana plant: phytochemistry and activities | |
KR20170133820A (en) | Composition for relieving menopausal symptom or osteoporosis | |
JPH07278001A (en) | External preparation for skin and bathing agent | |
EP0717613B1 (en) | Stable composition containing wheat sprout juice and process for producing it | |
KR102113431B1 (en) | Anti-inflammatory composition containing medicinal herbs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |